MBX Biosciences Inc

NASDAQ:MBXUnited States

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.

Contact Information

Headquarters

12406 Horesham StreetCARMEL, IN, United States 46032

Phone

317-989-3100

Fax

302-655-5049

Executives

President, Chief Executive Officer, Director

P. Hawryluk

Chief Financial Officer

Richard Bartram

Chief Medical Officer

Salomon Azoulay

Independent Director

Tiba Aynechi

Independent Director

James Cornelius